OBI's BOD resolved employees and amount granted
for the first issuance of RSU and authorized the
decision of record date to the Chairman
Date of events
2022/08/08
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/08/08
2.Company name:OBI Pharma Inc.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:Not applicable.
5.Cause of occurrence:
(1)The Annual Shareholders' Meeting of the Company resolved the issuance
of restricted stock awards of a total of 500,000 common shares, each
with a par value of NT$10, for a total amount of NT$5,000,000 on
2022/6/27. The issuance of restricted stock awards was approved by the
Financial Supervisory Commission on 2022/7/12, approval letter
No. 1110348619.
(2)The Company's Board of Directors resolved employees and amount granted
for the first issuance of restricted stock awards on 2022/8/8. The total
shares issued are 160,000 shares. The Chairman was authorized to decide
record date, issuance date, and any other matters not covered herein.
6.Countermeasures:None
7.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
OBI Pharma Inc. published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 August 2022 08:43:07 UTC.
OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.
OBI PHARMA, INC. 
